WO1996033731A1 - Procedes d'utilisation des facteurs neurotrophiques pour faciliter les greffes de neurones - Google Patents

Procedes d'utilisation des facteurs neurotrophiques pour faciliter les greffes de neurones Download PDF

Info

Publication number
WO1996033731A1
WO1996033731A1 PCT/US1996/005814 US9605814W WO9633731A1 WO 1996033731 A1 WO1996033731 A1 WO 1996033731A1 US 9605814 W US9605814 W US 9605814W WO 9633731 A1 WO9633731 A1 WO 9633731A1
Authority
WO
WIPO (PCT)
Prior art keywords
neurons
bdnf
mammal
neurotrophic factor
grafted
Prior art date
Application number
PCT/US1996/005814
Other languages
English (en)
Inventor
David M. Yurek
Stanley J. Wiegand
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Priority to AU55767/96A priority Critical patent/AU5576796A/en
Publication of WO1996033731A1 publication Critical patent/WO1996033731A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3

Abstract

La présente invention concerne un procédé permettant de favoriser l'intégration structurelle et fonctionnelle de neurones greffés à l'intérieur du système nerveux central chez un mammifère, ledit procédé consistant à administrer un facteur neurotrophique au système nerveux central du mammifère, ce qui permet de favoriser l'intégration structurelle et fonctionnelle des neurones greffés. De préférence, le facteur neurotrophique est administré au système nerveux central au cours d'une période du développement ontogénétique des neurones greffés pendant laquelle les neurones sont particulièrement sensibles au facteur neurotrophique. On peut choisir ce facteur neurotrophique dans le groupe constitué du NGF, du BDNF, de NT-3, de NT-4/5 et de leurs dérivés. Une autre possibilité consiste à choisir ce facteur neurotrophique dans le groupe constitué du CNTF, du GDNF et de leurs dérivés. On peut aussi administrer au moins deux des facteurs neurotrophiques appartenant au groupe constitué du CNTF, du GDNF, du NGF, du BDNF, de NT-3, de NT-4/5 et de leurs dérivés. De préférence, les neurones greffés sont des neurones dopaminergiques et sont contenus dans les tissus mésencéphaliques antérieurs foetaux. De préférence, également, le mammifère récepteur est un homme et l'on pratique la greffe au niveau du striatum du cerveau en guise de traitement de la maladie de Parkinson.
PCT/US1996/005814 1995-04-26 1996-04-26 Procedes d'utilisation des facteurs neurotrophiques pour faciliter les greffes de neurones WO1996033731A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU55767/96A AU5576796A (en) 1995-04-26 1996-04-26 Methods of using neurotrophic factors to enhance neuronal gr afts

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42787995A 1995-04-26 1995-04-26
US08/427,879 1995-04-26

Publications (1)

Publication Number Publication Date
WO1996033731A1 true WO1996033731A1 (fr) 1996-10-31

Family

ID=23696663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/005814 WO1996033731A1 (fr) 1995-04-26 1996-04-26 Procedes d'utilisation des facteurs neurotrophiques pour faciliter les greffes de neurones

Country Status (2)

Country Link
AU (1) AU5576796A (fr)
WO (1) WO1996033731A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056403A1 (fr) * 1997-06-13 1998-12-17 Roche Diagnostics Gmbh Amelioration de la regeneration des gaines de myeline
WO2000024415A2 (fr) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methodes de regulation de l'angiogenese et de l'integrite vasculaire a l'aide de ligands des recepteurs trk
EP1083227A1 (fr) * 1999-08-24 2001-03-14 Universite Libre De Bruxelles Structure génétique inductible/repressible par antibiotique pour la thérapie génique ou l'immunisation génique
WO2001019851A2 (fr) * 1999-09-16 2001-03-22 Neurotrophic Bioscience Inc. Facteurs stimulant la survie de neurones dopaminergiques et leur utilisation
US6322970B1 (en) 1997-09-02 2001-11-27 Sequenom, Inc. Mass spectrometric detection of polypeptides
US6780639B1 (en) * 1999-08-24 2004-08-24 Universite Libre De Bruxelles Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003199A1 (fr) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Procede ameliorant la differentiation et les chances de survie des cellules precurseurs neuronales

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003199A1 (fr) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Procede ameliorant la differentiation et les chances de survie des cellules precurseurs neuronales

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
25TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, SAN DIEGO, CALIFORNIA, USA, NOVEMBER 11-16, 1995. SOCIETY FOR NEUROSCIENCE ABSTRACTS 21 (1-3). 1995. 1562 *
ALTAR C.A. ET AL.: "Brain-derived neurotrophic factor augments rotational behavior and nigroastriatal dopamine turnover in vivo", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 89, no. 23, 1 December 1992 (1992-12-01), WASHINGTON US, pages 11347 - 11351, XP002010194 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; WIEGAND S J ET AL: "Effects of BDNF infusion on locomotor behavior and dopamine neurite outgrowth from fetal mesencephalic transplants.", XP002010196 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; YUREK D M ET AL: "Optimal effects of exogenous BDNF on grafts of fetal dopamine neurons coincides with the ontogenic period when dopamine content and BDNF expression increase within the striatum.", XP002010195 *
KANG U J ET AL: "Brain - derived neurotrophic factor ( BDNF )-secreting grafts protect dopaminergic neurons in vivo from partial 6-hydroxydopamine (6-OHDA) lesions.", KEYSTONE SYMPOSIUM ON THE MOLECULAR AND CELLULAR BASIS OF HUMAN NEURODEGENERATIVE DISEASE, BRECKENRIDGE, COLORADO, USA, APRIL 3-9, 1995. JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT 0 (21B). 1995. 109, XP002010193 *
LEVIVIER, MARC ET AL: "Intrastriatal implantation of fibroblasts genetically engineered to produce brain - derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson 's disease", J. NEUROSCI. (1995), 15(12), 7810-20, 1995, XP000578099 *
LINDVALL O ET AL: "Clinical application of cell transplantation and neurotrophic factors in CNS disorders.", CURRENT OPINION IN NEUROBIOLOGY 4 (5). 1994. 752-757, XP000578042 *
YUREK, DAVID M. ET AL: "BDNF enhances the functional reinnervation of the striatum by grafted fetal dopamine neurons", EXP. NEUROL. (1996), VOLUME DATE 1996, 137(1), 105-18, 1996, XP000578016 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056403A1 (fr) * 1997-06-13 1998-12-17 Roche Diagnostics Gmbh Amelioration de la regeneration des gaines de myeline
US6322970B1 (en) 1997-09-02 2001-11-27 Sequenom, Inc. Mass spectrometric detection of polypeptides
WO2000024415A2 (fr) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methodes de regulation de l'angiogenese et de l'integrite vasculaire a l'aide de ligands des recepteurs trk
WO2000024415A3 (fr) * 1998-10-28 2000-08-03 Cornell Res Foundation Inc Methodes de regulation de l'angiogenese et de l'integrite vasculaire a l'aide de ligands des recepteurs trk
US8853163B2 (en) 1998-10-28 2014-10-07 Cornell Research Foundation, Inc. Methods for increasing vascular density and maintaining viability of microvascular endothelial cells using trk receptor ligands
US7723293B2 (en) 1998-10-28 2010-05-25 Cornell Research Foundation, Inc. Methods for increasing capillary density and maintaining viability of microvascular cardiac endothelial cells using trk receptor ligands
EP1083227A1 (fr) * 1999-08-24 2001-03-14 Universite Libre De Bruxelles Structure génétique inductible/repressible par antibiotique pour la thérapie génique ou l'immunisation génique
US6780639B1 (en) * 1999-08-24 2004-08-24 Universite Libre De Bruxelles Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization
WO2001019851A3 (fr) * 1999-09-16 2001-09-20 Neurotrophic Bioscience Inc Facteurs stimulant la survie de neurones dopaminergiques et leur utilisation
WO2001019851A2 (fr) * 1999-09-16 2001-03-22 Neurotrophic Bioscience Inc. Facteurs stimulant la survie de neurones dopaminergiques et leur utilisation
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
US8883716B2 (en) 2003-12-01 2014-11-11 Medtronic, Inc. Method for treating damaged tissue of the CNS
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof

Also Published As

Publication number Publication date
AU5576796A (en) 1996-11-18

Similar Documents

Publication Publication Date Title
Yurek et al. BDNF enhances the functional reinnervation of the striatum by grafted fetal dopamine neurons
US8158578B2 (en) Methods for treating neurological deficits
Anderson et al. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease.
Bamber et al. Neurotrophins BDNF and NT‐3 promote axonal re‐entry into the distal host spinal cord through Schwann cell‐seeded mini‐channels
Andsberg et al. Amelioration of ischaemia‐induced neuronal death in the rat striatum by NGF‐secreting neural stem cells
Guest et al. Influence of IN‐1 antibody and acidic FGF‐fibrin glue on the response of injured corticospinal tract axons to human Schwann cell grafts
Tomlinson et al. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors
Tomlinson et al. Neurotrophins and peripheral neuropathy
Hagg Neurotrophins prevent death and differentially affect tyrosine hydroxylase of adult rat nigrostriatal neuronsin vivo
Clatterbuck et al. Further characterization of the effects of brain‐derived neurotrophic factor and ciliary neurotrophic factor on axotomized neonatal and adult mammalian motor neurons
US6264941B1 (en) Compositions for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
Shibayama et al. Neurotrophin‐3 prevents death of axotomized Clarke's nucleus neurons in adult rat
JPH09508002A (ja) 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル
US5580555A (en) Regeneration of injured central nervous system axons
Fertig et al. Enhancement of axonal regeneration in the brain of the rat by corticotrophin and triiodothyronine
WO1996033731A1 (fr) Procedes d'utilisation des facteurs neurotrophiques pour faciliter les greffes de neurones
Santos et al. Local administration of neurotrophic growth factor in subcutaneous silicon chambers enhances the regeneration of the sensory component of the rat sciatic nerve
Agoston et al. Selective up-regulation of neuropeptide synthesis by blocking the neuronal activity: galanin expression in septohippocampal neurons
AU677951B2 (en) Prevention of retinal injury and degeneration by specific factors
Hagg Neurotrophic factors
Olson Grafts and growth factors in CNS: basic science with clinical promise
Yurek et al. Optimal effectiveness of BDNF for fetal nigral transplants coincides with the ontogenic appearance of BDNF in the striatum
Nagtegaal et al. Trophic and tropic factors in the development of the central nervous system
Sievers et al. Regeneration in the optic nerve of adult rats: influences of cultured astrocytes and optic nerve grafts of different ontogenetic stages
Schonfeld et al. Neuronotrophic factors: Effects on central cholinergic regeneration in vivo

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA